MAP4K4 and lung adenocarcinoma: This finding might have important clinical implications: It suggests MAP4K4‐targeted therapy as a novel treatment option for the RAS‐mutated lung adenocarcinoma patients, which currently has few treatment options (Ahearn et al., 2012).